Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 92

Related Citations for PubMed (Select 22749734)

1.

Will biomarkers save prostate cancer screening?

Cooperberg MR.

Eur Urol. 2012 Dec;62(6):962-3; discussion 964-5. doi: 10.1016/j.eururo.2012.06.034. Epub 2012 Jun 27. No abstract available.

PMID:
22749734
2.

[New biomarkers in prostate cancer].

Provenzano M.

Praxis (Bern 1994). 2012 Jan 18;101(2):115-21. doi: 10.1024/1661-8157/a000819. Review. German.

PMID:
22252593
3.

Prostate cancer.

Nelson WG, De Marzo AM, Isaacs WB.

N Engl J Med. 2003 Jul 24;349(4):366-81. Review. No abstract available.

PMID:
12878745
4.

[High-grade prostatic intraepithelial neoplasia: the only accepted prostate cancer precursor lesion].

Braun M, Perner S.

Pathologe. 2011 Nov;32 Suppl 2:237-41. doi: 10.1007/s00292-011-1500-9. Review. German.

PMID:
21845356
5.

Prostate cancer: towards the standardization and synthesis of morphology, genetics, and prognosis.

Berney D, Cheng L.

Histopathology. 2012 Jan;60(1):1-3. doi: 10.1111/j.1365-2559.2011.04080.x. Review.

PMID:
22212074
6.

[Morphometric diagnostics of the prostate precancer and cancer by examination of ploidy].

Gundorova LV, Avtandilov GG, Saniev KB, Zaĭrat'iants OV.

Arkh Patol. 2003 Jul-Aug;65(4):46-50. Russian.

PMID:
14518195
7.

Benign prostatic hyperplasia and prostate cancer.

Guess HA.

Epidemiol Rev. 2001;23(1):152-8. Review. No abstract available.

8.

Editorial comment: Critical role of prostate biopsy mortality in the number of years of life gained and lost within a prostate cancer screening programme.

Albertsen PC.

BJU Int. 2012 Dec;110(11):1653. doi: 10.1111/j.1464-410X.2012.11522.x. Epub 2012 Sep 18. No abstract available.

PMID:
22984891
9.

The role of tissue microarrays in prostate cancer biomarker discovery.

Datta MW, True LD, Nelson PS, Amin MB.

Adv Anat Pathol. 2007 Nov;14(6):408-18. Review.

PMID:
18049130
10.

The case for prostate cancer screening.

Andriole GL.

Semin Urol. 1993 May;11(2):50-3. Review.

PMID:
7689738
11.
12.

Pathology of prostate cancer.

Che M, Grignon D.

Cancer Metastasis Rev. 2002;21(3-4):381-95. Review. No abstract available.

PMID:
12549773
13.

The natural history of prostatic carcinoma.

Busch C.

Scand J Urol Nephrol Suppl. 1988;110:23-9. No abstract available.

PMID:
3187413
14.

New concepts in the pathology of prostatic epithelial carcinogenesis.

De Marzo AM, Putzi MJ, Nelson WG.

Urology. 2001 Apr;57(4 Suppl 1):103-14. Review.

PMID:
11295606
15.

Androgen action during prostate carcinogenesis.

Wang D, Tindall DJ.

Methods Mol Biol. 2011;776:25-44. doi: 10.1007/978-1-61779-243-4_2. Review.

PMID:
21796518
16.

PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer.

Bismar TA, Yoshimoto M, Vollmer RT, Duan Q, Firszt M, Corcos J, Squire JA.

BJU Int. 2011 Feb;107(3):477-85. doi: 10.1111/j.1464-410X.2010.09470.x.

PMID:
20590547
17.
19.

Comments on the article "Biomarkers for prostate cancer" by Eric Schiffer.

Marshall S.

World J Urol. 2009 Aug;27(4):577-8. doi: 10.1007/s00345-009-0435-8. Epub 2009 Jun 19. No abstract available.

20.

HER2 expression and gene amplification in pT2a Gleason score 6 prostate cancer incidentally detected in cystoprostatectomies: comparison with clinically detected androgen-dependent and androgen-independent cancer.

Montironi R, Mazzucchelli R, Barbisan F, Stramazzotti D, Santinelli A, Scarpelli M, Lòpez Beltran A.

Hum Pathol. 2006 Sep;37(9):1137-44. Epub 2006 Jun 21.

PMID:
16938518
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk